Bis-indolic derivatives, their uses in particular as antibacterials

1. A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable vehicle,

wherein:

X and X′ represent independently from each other O or S, and

(a) R 1 , R 2 , R 3 , R 4 , R 5 , R′ 1 , R′ 2 , R′ 3 , R′ 4 and R′ 5 represent independently from each other:

H,

a linear or branched (C 1 -C 7 )alkyl optionally substituted by: a halogen, a hydroxyl group, a OR a or NR a R b , wherein R a and R b represent: H, a linear or branched (C 1 -C 7 )-alkyl, (C 3 -C 7 )-cycloalkyl, an aryl substituted or not, CH 2 -aryl, CO—(C 1 -C 7 )-alkyl, CO-aryl, CO 2 — (C 1 -C 7 )-alkyl, CO 2 -aryl, wherein aryl is a substituted or not aromatic group or a substituted or not heteroaromatic group,

a (C 3 -C 7 )-cycloalkyl, an aryl substituted or not, CH 2 -aryl, CO—(C 1 -C 7 )-alkyl, CO-aryl, CO 2 —(C 1 -C 7 )-alkyl, CO 2 -aryl, wherein aryl is a substituted or not aromatic group or a substituted or not heteroaromatic group,

F, Cl, Br, I, CF 3 , OH, OR a , OCF 3 , COCF 3 , NH 2 , NHR a , NR a R b , wherein R a and R b represent: H, a linear or branched (C 1 -C 7 )-alkyl, a (C 3 -C 7 )-cycloalkyl, an aryl substituted or not, CH 2 -aryl, CO—(C 1 -C 7 )-alkyl, CO-aryl, CO 2 —(C 1 -C 7 )-alkyl, CO 2 -aryl, wherein aryl is a substituted or not aromatic group or a substituted or not heteroaromatic group,

CN and NO 2 , provided that R 1 , R 2 , R 3 , R 4 , R 5 , R′ 1 are different from CN and NO 2 ,

(CH 2 ) n —Z, —(CH 2 ) n —OH, —(CH 2 ) n —CO 2 (C 1 -C 7 )-alkyl, —(CH 2 ) n —CO 2 wherein n=2 to 12, Z is a halogen, and alkyl being as defined above,

R represents H, a (C 1 -C 7 )-alkyl, CH 2 NHCO 2 —(C 1 -C 7 )-alkyl, CH 2 NHCO 2 —(C 3 -C 7 )-cycloalkyl, CO 2 H, CO 2 —(C 1 -C 7 )-alkyl, CO 2 —(C 3 -C 7 )-cycloalkyl, (CH 2 ) n OH, CH 2 NH(CH 2 ) n —OH, CH 2 NH(CH 2 ) n —NR a R b , CONH—(C 1 -C 7 )-alkyl, CONH—(C 3 -C 7 )-cycloalkyl, CONH-aryl, CONH—(CH 2 ) n OH, CONH—(CH 2 ) n NR a R b , wherein n=2 to 12 and R a , R b , aryl and alkyl being as defined above,

R 6 and R′ 6 represent independently from each other H, (C 1 -C 7 ) -alkyl, SO 2 aryl, aryl being as defined above, OH, O—(C 1 -C 7 )-alkyl, CO—(C 1 -C 7 )-alkyl, CO-aryl, CH 2 NH 2 , CH 2 NHRa, CH 2 N a R b , Si(R c ) 3 , the Rc groups being identical or different and representing independently of each other a linear or branched (C 1 -C 7 )-alkyl, a (C 3 -C 7 )-cycloalkyl, or an aryl, aryl and alkyl being as defined above, and

R 7 represents H, OH, OR a , R a being as defined above;

or b) R and R 7 are joined together to form a cycle of formula I-a:

wherein Y represents:

N—R 8 , wherein R 8 represents H, (C 1 C 7 )-alkyl, (C 3 -C 7 )-cycloalkyl, CO—(C 1 -C 7 )-alkyl, CO—(C 3 -C 7 )-cycloalkyl, CO 2 —(C 1 -C 7 )-alkyl, CO 2 —(C 3 -C 7 )-cycloalkyl,

O, S,

CH 2 , CHR 8 wherein R 8 represents (C 2 -C 7 )-alkyl, (C 3 -C 7 )-cycloalkyl, CO—(C 1 -C 7 )-alkyl, CO—(C 3 -C 7 )-cycloalkyl, CO 2 —(C 1 -C 7 )-alkyl, CO 2 —(C 3 -C 7 )-cycloalkyl, and

m=0, 1

said cycle being optionally substituted by OH, a linear or branched O(C 1 -C 7 )-alkyl, a O(C 3 -C 7 )-cycloalkyl, NH 2 , or NR a R b , R a and R b being as defined above, and

R 1 , R 2 , R 3 , R 4 , R 5 , R′ 1 R′ 2 , R′ 3 , R′ 4 , R′ 5 , R 6 and R′ 6 being as defined above,

or c) R and R 7 are joined together to form a cycle of formula I-b:

wherein Y represents:

C, CR 8 , wherein R 8 represents (C 1 -C 7 )-alkyl, (C 3 -C 7 )-cycloalkyl, CO—(C 1 -C 7 )-alkyl, CO—(C 3 -C 7 )-cycloalkyl, CO 2 —(C 1 -C 7 )-alkyl, CO 2 —(C 3 -C 7 )-cycloalkyl, and

m=1

R 1 , R 2 , R 3 , R 4 , R 5 , R′ 1 , R′ 2 , R′ 3 , R′ 4 , R′ 5 , R 6 and R′ 6 being as defined above,

and their pharmaceutically acceptable salts.

2. The pharmaceutical composition according to claim 1 , administrable by oral route at a dose of from 10 mg/kg to 200 mg/kg.

3. The pharmaceutical composition according to claim 1 , administrable by intravenous route at a dose of from 5 μg/kg to 50 mg/kg.

4. The pharmaceutical composition according to claim 1 , further comprising:

at least one antibiotic compound,

said pharmaceutical composition being used for simultaneous or separate use, or use spread over time, intended for the treatment of pathologies associated with bacterial infections for which a resistance to said at least one antibiotic exists.

5. The pharmaceutical composition according to claim 1 , wherein:

X and X′ are as previously defined,

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R′ 1 , R′ 2 , R′ 3 , R′ 4 , R′ 5 and R′ 6 are as previously defined,

R represents H, a (C 1 -C 7 )-alkyl, CH 2 NHCO 2 —(C 1 -C 7 )-alkyl, CH 2 NHCO 2 —(C 3 -C 7 )-cycloalkyl, CO 2 H, CO 2 —(C 1 -C 7 )-alkyl, CO 2 —(C 3 -C 7 )-cycloalkyl, (CH 2 ) n OH, CH 2 NH(CH 2 ) n —OH, CH 2 NH(CH 2 ) n —NR a R b , CONH—(C 1 -C 7 )-alkyl, CONH—(C 3 -C 7 )-cycloalkyl, CONH-aryl, CONH—(CH 2 ) n OH, CONH—(CH 2 ) n NR a R b , wherein n=2 to 12, and R a , R b , aryl and alkyl being as previously defined, and

R 7 represents H, OH, OR, R a being as previously defined.

6. The pharmaceutical composition according to claim 1 , wherein:

X and X′ are as previously defined,

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 R′ 1 , R′ 2 , R′ 3 , R′ 4 , R′ 5 and R′ 6 are as previously defined, and

R and R 7 are joined together to form a cycle of formulas (I-a) and (I-b) as previously defined.

7. The pharmaceutical composition according to claim 1 , wherein said compound is of formula II:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 R′ 1 , R′ 2 , R′ 3 , R′ 4 , R′ 5 and R′ 6 are as previously defined.

8. The pharmaceutical composition according to claim 1 , wherein said compound is of formula III:

wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 6 R′ 1 , R ′ 2 , R′ 3 , R′ 4 , R′ 5 and R are as previously defined.

9. The pharmaceutical composition according to claim 1 , wherein said compound is of formula IV:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 R′ 1 , R′ 2 , R′ 3 , R′ 4 and R are as previously defined.

10. The pharmaceutical composition according to claim 1 , wherein said compound is of formula V

wherein:

R 3 , R 4 , R′ 3 and R′ 4 each independently represents H, F, Cl, Br, I, and

R represents a (C 2 -C 7 )-alkyl, CH 2 NHCO 2 —(C 1 -C 7 )-alkyl, CO 2 H, CO 2 —(C 1 -C 7 )-alkyl, CONH—(CH 2 ) n OH, (CH 2 ) n OH, CH 2 NH(CH 2 ) n —OH, CH 2 NH(CH 2 ) n —NR a R b , CONH—(CH 2 ) n NR a R b .

11. The pharmaceutical composition according to claim 10 , wherein at least one of R 3 , R 4 , R′ 3 and R′ 4 represents F, Cl, Br, I.

12. The pharmaceutical composition according to claim 1 , wherein said compound is of general formula VI:

wherein:

R 3 and R′ 3 each independently represents H, F, Cl, Br, I, and at least one of R 3 and R′ 3 represents F, Cl, Br, I, and R represents a (C 1 -C 7 )-alkyl, CH 2 NHCO 2 —(C 1 -C 7 )-alkyl, CO 2 H, CO 2 —(C 1 -C 7 )-alkyl, CONH—(CH 2 ) n OH, (CH 2 ) n OH, CH 2 NH(CH 2 ) n —OH, CH 2 NH(CH 2 ) n —NR a R b , CONH—(CH 2 ) n NR a R b ,

in particular compounds of formula VI selected from the group consisting of:

or compounds of the following general formula VII:

wherein:

R 4 and R′ 4 each independently represents H, F, Cl, Br, I, and at least one of R 4 and R′ 4 represents F, Cl, Br, I, and

R represents a (C 1 -C 7 )-alkyl, CH 2 NHCO 2 (C 1 -C 7 )-alkyl, CO 2 H, CO 2 —(C 1 -C 7 )-alkyl, CONH—(CH 2 ) n OH, (CH 2 ) n OH, CH 2 NH(CH 2 ) n —OH, CH 2 NH(CH 2 ) n —NR a R b , CONH—(CH 2 ) n —NR a R b ,

in particular compounds having the following structure:

or compounds of the following formula V-1:

wherein:

R represents a (C 1 -C 7 )-alkyl, CH 2 NHCO 2 —(C 1 -C 7 )-alkyl, CO 2 H, CO 2 —(C 1 -C 7 )-alkyl, CONH—(CH 2 ) n OH, (CH 2 ) n OH, CH 2 NH(CH 2 ) n —OH, CH 2 NH(CH 2 ) n —NR a R b , CONH—(CH 2 ) n NR a R b , in particular compounds having the following structure:

or compounds of the following general formula VIII:

wherein:

Y=N—R 8 =NBoc or NH, or

Y=CH 2 , CH—R 8 , R 8 being as previously defined,

R 3 , R 4 , R′ 3 and R′ 4 each independently represents H, F, Cl, Br, I, and

m=0 or 1,

in particular compounds selected from the group consisting of:

13. The pharmaceutical composition according to claim 1 , wherein said compound is in an effective amount for having an antibacterial activity and/or being a NorA efflux pump inhibitor.

14. The pharmaceutical composition according to claim 13 , wherein the antibacterial activity is against Gram-positive and Gram-negative bacteria.

15. The pharmaceutical composition according to claim 13 , wherein said bacteria are resistant to conventional antibiotics.

16. The pharmaceutical composition according to claim 13 , wherein the antibacterial activity is against Staphylococcus species, in particular Staphylococcus aureus , especially Staphylococcus aureus resistant to β-lactams, including methicillin-resistant strains (also referred as MRSA), Staphylococcus aureus resistant to glycopeptides, vancomycin-resistant or glycopeptide-resistant strains (also referred as VISA or GISA), and Staphylococcus aureus resistant to fluoroquinolones.

17. The pharmaceutical composition according to claim 13 , having further an antifungal and/or antiviral activity.

18. The pharmaceutical composition according to claim 4 , wherein said at least one antibiotic is selected from the group consisting of the fluoroquinolones family, ciprofloxacin, norfloxacin, pefloxacin, enofloxacin, ofloxacin, levofloxacin and moxifloxacin.

19. A method for an antibacterial treatment comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 1 .

20. A method for an antibacterial treatment comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 4 and further at least one antibiotic compound.